[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100397257":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":129,"collaborators":25,"id":131,"slug":132,"hasResults":133,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":25,"eligibilityCriteria":137,"healthyVolunteers":138,"sex":139,"minAge":140,"maxAge":25,"enrollmentInfo":141,"targetDuration":25,"studyType":144,"phases":145,"briefSummary":147,"conditions":148,"keywords":25,"overallStatus":150,"whyStopped":25,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":155,"completionDateStruct":156,"leadSponsor":158,"locationsCount":159},{"fullName":5,"class":6},"Reig Jofre Group","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Manremyc","EXPERIMENTAL","Participants will receive daily oral administration of a capsule of Manremyc for 14 days in the morning with breakfast",[13],"Dietary Supplement: Manremyc",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants will receive daily oral administration of a capsule of Placebo for 14 days in the morning with breakfast",[19],"Dietary Supplement: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","Manremyc is composed by 10E5 heat-inactivated Mycobacterium s. manresensis bacilli",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Same excipients than active arm without bacilli.",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Pere Joan Cardona, MD, PhD","CONTACT","+34934978681","pjcardona@igtp.cat",[36,58,75,98,113],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"CAP Cornellà (La Gavarra)","NOT_YET_RECRUITING","Cornellà de Llobregat","Barcelona","08940","Spain","ES",{"type":45,"coordinates":46},"Point",[47,48],2.08333,41.35,{"lat":48,"lon":47},[51,55],{"name":52,"role":32,"phone":53,"phoneExt":25,"email":54},"Mª Betlem Salvador, Dr.","+34 93 857 55 45","bsalvador@ambitcp.catsalut.net",{"name":56,"role":32,"phone":53,"phoneExt":25,"email":57},"Sofía Berlanga","sberlanga.cp.ics@gencat.cat",{"facility":59,"status":38,"city":60,"state":40,"zip":61,"country":42,"countryCode":43,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"CAP Maresme","Mataró","08303",{"type":45,"coordinates":63},[64,65],2.4445,41.54211,{"lat":65,"lon":64},[68,72],{"name":69,"role":32,"phone":70,"phoneExt":25,"email":71},"Pere Torán, Dr.","+34 93 741 60 73","ptoran.bnm.ics@gencat.cat",{"name":73,"role":32,"phone":70,"phoneExt":25,"email":74},"Noemí Lamonja","noemilamonjavicente@gmail.com",{"facility":76,"status":77,"city":78,"state":40,"zip":79,"country":42,"countryCode":43,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Cap Sant Fèlix","RECRUITING","Sabadell","08203",{"type":45,"coordinates":81},[82,83],2.10942,41.54329,{"lat":83,"lon":82},[86,90,94,96],{"name":87,"role":32,"phone":88,"phoneExt":25,"email":89},"Concepció Violant, Dr.","93 693 27 32","cviolanf.mn.ics@gencat.cat",{"name":91,"role":32,"phone":92,"phoneExt":25,"email":93},"Mª José Argerich, Dr.","675785198","mjargerich.mn.ics@gencat.cat",{"name":87,"role":95,"phone":25,"phoneExt":25,"email":25},"PRINCIPAL_INVESTIGATOR",{"name":91,"role":97,"phone":25,"phoneExt":25,"email":25},"SUB_INVESTIGATOR",{"facility":99,"status":38,"city":100,"state":101,"zip":102,"country":42,"countryCode":43,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"EAP Riu Nord","Santa Coloma de Gramenet","BArcelona","08921",{"type":45,"coordinates":104},[105,106],2.2081,41.45152,{"lat":106,"lon":105},[109,111],{"name":110,"role":32,"phone":25,"phoneExt":25,"email":25},"Magda Alemany, Dr.",{"name":112,"role":32,"phone":25,"phoneExt":25,"email":25},"Eli Sánchez",{"facility":114,"status":38,"city":115,"state":25,"zip":116,"country":42,"countryCode":43,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"Hospital Universitari Germans Trias i Pujol UBP Riscos Laborals, Badalona,","Badalona","08916",{"type":45,"coordinates":118},[119,120],2.24741,41.45004,{"lat":120,"lon":119},[123,127,128],{"name":124,"role":32,"phone":125,"phoneExt":25,"email":126},"Joan Matllo, Dr.","670282689","jmatlloaguilar@gencat.cat",{"name":31,"role":95,"phone":25,"phoneExt":25,"email":25},{"name":124,"role":97,"phone":25,"phoneExt":25,"email":25},{"type":130,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100397257","clinical-trial-to-evaluate-the-efficacy-of-food-supplement-manremyc-against-sars--cov-2-infection-covid-19-in-healthcare-workers-100397257",false,"NCT04452773","Clinical Trial to Evaluate the Efficacy of Food Supplement Manremyc® Against SARS- COV-2 Infection (COVID-19) in Healthcare Workers","Double-blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of the Manremyc® Food Supplement to Prevent SARS-CoV-2 Infection","Inclusion Criteria:\n\n1. Sign the Informed Consent before initiating the selection procedures.\n2. Health system workers working in contact with subjects potentially infected with SARS-CoV-2.\n3. People ≥ 18 years.\n4. Availability to meet the requirements of the protocol.\n5. Negative Rapid Serological Test of SARS-CoV-2\n\nExclusion Criteria:\n\n1. Previous SARS-CoV-2 infection\n2. Pregnancy or breastfeeding.\n3. Suspected of active viral or bacterial infection.\n4. Symptoms compatible with COVID-19, despite a negative PCR test.\n5. Vaccination in the last 4 weeks or planned vaccination during the study period, regardless of the type of vaccine.\n6. Participation in a research that requires experimental intervention (does not include observational studies) in the previous month before signing the Consent or during the study.\n7. Severely immunocompromised people. This exclusion category includes:\n\n   1. Subjects with human immunodeficiency virus (HIV-1).\n   2. Neutropenic subjects with less than 500 neutrophils \u002F mm3.\n   3. Subjects with solid organ transplantation.\n   4. Subjects with bone marrow transplantation.\n   5. Subjects undergoing chemotherapy.\n   6. Subjects with primary immunodeficiency.\n   7. Severe lymphopenia with less than 400 lymphocytes \u002F mm3.\n   8. Treatment with any anti-cytokine therapy.\n   9. Oral treatment with steroids, defined as daily doses of 10 mg prednisone or equivalent for more than 3 months.\n8. Malignancy, or active solid or non-solid lymphoma from the previous two years.\n9. BCG vaccination in the last 10 years.\n10. Treatment with Manremyc® for the last 6 months.\n11. Chloroquine or hydroxychloroquine administration in the last two weeks.\n12. Direct involvement in the design or execution of the MANRECOVID19 clinical trial.\n13. Retirement, transfer, long-term leave (\\> 1 month) due to scheduled surgery or any other event that makes it impossible to work in person at your health center during the months following the recruitment to the study.\n14. Employee at the health center \\\u003C22 hours per week.\n15. Do not have a smartphone.\n16. Detection by the investigator of lack of knowledge or willingness to participate and comply with all requirements of the protocol.\n17. Any other findings that, at the discretion of the investigator, may compromise compliance with the protocol or that may influence significantly the interpretation or the results of the effects of probiotic.",true,"ALL","18 Years",{"count":142,"type":143},315,"ESTIMATED","INTERVENTIONAL",[146],"NA","The purpose of this study is to assess the efficacy of Manremyc® food supplement for reduce the incidence of SARS-CoV-2 infection in a high risk population, as healthcare workers.",[149],"COVID19","UNKNOWN","2020-07-14",{"date":153,"type":154},"2020-07-15","ACTUAL",{"date":151,"type":154},{"date":157,"type":143},"2021-12",{"name":5,"class":6},5]